To learn more about AYVAKIT® (avapritinib), visit the product website or download prescribing information below.
To learn more about AYVAKYT® (avapritinib), go to the prescribing information below.
To learn more about GAVRETO® (pralsetinib), visit the product website or download prescribing information below.
GAVRETO is jointly commercialized in the U.S. by Blueprint Medicines and Genentech, a wholly owned member of the Roche Group, under Blueprint Medicines’ collaboration with Roche. For information about U.S. patient assistance programs, visit http://www.Genentech-Access.com.
Roche has exclusive commercialization rights for GAVRETO outside of the U.S., excluding the CStone Pharmaceuticals territory (Mainland China, Hong Kong, Macau and Taiwan).
These products may not be approved and/or licensed in all countries where this website is accessible.